MINT – Restrictive or Liberal Transfusion Strategy in Myocardial Infarction

Restrictive or Liberal Transfusion Strategy in Myocardial Infarction and Anemia Carson et al. NEJM 2023 DOI: 10.1056/NEJMoa2307983   Clinical Question In patients with myocardial infarction and anaemia, does a restrictive or liberal transfusion strategy decrease myocardial ischaemia or death at 30 days?  Myocardial Ischemia and Transfusion (MINT) Trial  Background Anaemia is common in patients with acute myocardial infarction and may exacerbate […]

Continue reading »

FARES II: PCC vs FFP in Cardiac Surgery

Prothrombin Complex Concentrate vs Frozen Plasma for Coagulopathic Bleeding in Cardiac Surgery The FARES-II Multicenter Randomized Clinical Trial Karkouthi. JAMA 2025; doi:10.1001/jama.2025.3501 Clinical Question In adults undergoing cardiac surgery with cardiopulmonary bypass, is the use of a 4-factor prothrombin complex concentrate (PCC), compared to fresh frozen plasma (FFP), safe and efficacious in treating active or anticipated bleeding? Background Bleeding post […]

Continue reading »

Clinical Decisions on Beta Blockers After MI

Clinical Question In adults with acute myocardial infarction and preserved left ventricular ejection fraction (LVEF), does initiating beta-blocker therapy at discharge, compared with no beta-blocker therapy, reduce the risk of death or recurrent myocardial infarction?   Background Beta-blockers have long been a cornerstone of post–myocardial infarction care, largely based on trials conducted in the pre-reperfusion era. However, with modern advances […]

Continue reading »

DanGer Shock – Microaxial Flow Pump in Infarct-Related Cardiogenic Shock

Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock Møller JE et al. 2024. NEJM. DOI: 10.1056/NEJMoa2312572 Clinical Question In adults presenting with STEMI and cardiogenic shock does the use of a microaxial flow pump (Impella CP) compared to standard care reduce death from any cause at day 180? Background Cardiogenic shock is a frequent complication of STEMI and […]

Continue reading »

STRESS-L: Landiolol and Organ Failure in Patients With Septic Shock

Landiolol and Organ Failure in Patients With Septic Shock Whitehouse. JAMA Published online October 25, 2023. doi:10.1001/jama.2023.20134 Clinical Question In patients with tachycardia and septic shock who are treated with high dose norepinephrine does the use of β-blockade for up to 14 days reduce organ failure compared to standard care? Background Many view the use of β-blockade as contentious in […]

Continue reading »

ECLS-Shock – Extracorporeal Life Support in Infarct-Related Cardiogenic Shock

Extracorporeal Life Support in Infarct-Related Cardiogenic Shock Thiele H. NEJM 2023; Online ahead of print. doi:10.1056/NEJMoa2307227 Clinical Question In patients presenting with acute myocardial infarction complicated by cardiogenic shock undergoing revascularisation, does the early unselected application of extracorporeal life support reduce mortality from any cause at day 30? Background The use of venoarterial extracorporeal membrane oxygenation (VA ECMO), which is […]

Continue reading »
1 2 3 5